Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
June 24, 2026 | AI, HEOR, Market Access, RWE, evidence, evidence synthesis, genesis, literature reviews, slr
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it yourself. Run it with Genesis. Or have Genesis run it for you.”
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers.
Developed in-house by Genesis scientists and refined through two years of real-world application in client evidence work, EVID AI provides a structured environment for conducting evidence synthesis activities, from rapid evidence queries and targeted literature reviews to ongoing literature surveillance and end-to-end systematic reviews.
Designed as a flexible working model, the EVID AI free access program enables teams and individuals to run projects independently, collaborate with Genesis experts, or delegate entirely, depending on their needs.
“Run it yourself. Run it with Genesis. Or have Genesis run it for you.”
A single environment for evidence work
EVID AI brings evidence activities into one place, removing fragmentation across tools and processes, providing teams with a practical way to apply the same structured approaches used in evidence work within a single platform and workflow. It enables teams to:
- Identify and assess relevant literature
- Manage structured review workflows
- Monitor evolving evidence landscapes
- Support decision-making with clearer, more structured outputs
Designed for life sciences decision-making
EVID AI has been built and refined within Genesis’ own work, reflecting evidence synthesis needs across HEOR, RWE, Medical Affairs, and Market Access.
By aligning with real-world workflows, it supports faster, more informed decisions across the product lifecycle, supporting how therapies are evaluated, understood, and ultimately made available to patients.
Access and next steps
Approved users will receive free platform access through 31 December 2026, with optional access to Genesis expertise for protocol design, search strategy, screening, interpretation, and full project delivery.
Expert support remains separate from the platform offer and is provided based on user needs. Interested individuals can request access via the Genesis website.
Request free access at genesisrg.com.
About Genesis Research Group
EVIDENCE. EXPERIENCE. JUDGMENT.
Genesis Research Group is a global life sciences consulting firm specializing in evidence generation, health economics and outcomes research, real-world evidence, market access, pricing strategy, and stakeholder insights. Genesis combines rigorous evidence, deep expertise, and practical judgment to help companies reduce uncertainty and make better decisions across development, launch, access, and commercialization.
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research Insights & Evidence webinar 20 Oct: Reserve your place!
Join Priti Jhingran of Genesis Research and Tijana Ignjatovic of Market Access Transformation (MAT) for their webinar ‘Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to…
Leading pharmaceutical executive Jennifer Fillman joins evidence-based solution provider Genesis Research as Chief Financial Officer
International health economics and outcomes research (HEOR) and real-world evidence (RWE) organization Genesis Research has announced the appointment of Jennifer Fillman as its new Chief Financial Officer. Prior to joining…
Genesis Research and Syapse combine forces to offer RWE and data to oncology innovators
Genesis Research is delighted to announce a strategic partnership with Syapse®, combining the expertise and resources of both companies to better serve clients that are developing new oncology innovations.
Genesis Research and Clinical Outcomes Solutions announce innovative partnership
International Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) organization Genesis Research is delighted to announce an exciting new partnership with Clinical Outcomes Assessment (COA) specialist Clinical Outcomes…
Genesis Research Acquires Market Access Transformation
Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services, has entered into a definitive agreement to acquire Market Access Transformation (“MAT”),…
GHO Capital Acquires Genesis Research
GHO Capital Partners LLP, the European specialist investor in global healthcare, announces the acquisition of Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes…